mRNA profiling on Axl inhibitor TP0903 treated CART19 compared to untreated CART19 produced from normal donors. mRNA profiling on Axl inhibitor TP0903 treated CART19 compared to untreated CART19 produced from normal donors

RNA sequencing was performed on three biological replicates of DMSO treated CART19 (control) and TP0903 treated CART19 produced from normal donors. Overall design: T cells from normal donors were transduced with a replication-incompetent lentiviral vector expressing a second-generation chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (FMC63) fused to 4-1BB and CD3ζ intracellular domains as previously described. DMSO or TP-0903 treated CART19 were stimulated with CD19+ cell line Jeko-1 for 24 hours and CART19 were isolated with CD20 microbeads. After confirming CART19 isolation was performed successfully with flow cytometry (>99% purity), RNA was isolated from CART19.